Treatment of murine fusariosis with SCH 56592

M. Lozano-Chiu; S. Arikan; V. L. Paetznick; E. J. Anaissie; D. Loebenberg; J. H. Rex

doi:10.1128/aac.43.3.589

Treatment of murine fusariosis with SCH 56592

M. Lozano-Chiu
, S. Arikan
, V. L. Paetznick
, E. J. Anaissie
, D. Loebenberg
, J. H. Rex

Research output: Contribution to journal › Article › peer-review

77 Citations (Scopus)

Abstract

Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

Original language	English
Pages (from-to)	589-591
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	43
Issue number	3
DOIs	https://doi.org/10.1128/aac.43.3.589
Publication status	Published - Mar 1999
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/aac.43.3.589

Cite this

@article{d046cdf4de0b4d77a2b5072c0b01e76a,

title = "Treatment of murine fusariosis with SCH 56592",

abstract = "Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.",

author = "M. Lozano-Chiu and S. Arikan and Paetznick, \{V. L.\} and Anaissie, \{E. J.\} and D. Loebenberg and Rex, \{J. H.\}",

year = "1999",

month = mar,

doi = "10.1128/aac.43.3.589",

language = "English",

volume = "43",

pages = "589--591",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - Treatment of murine fusariosis with SCH 56592

AU - Lozano-Chiu, M.

AU - Arikan, S.

AU - Paetznick, V. L.

AU - Anaissie, E. J.

AU - Loebenberg, D.

AU - Rex, J. H.

PY - 1999/3

Y1 - 1999/3

N2 - Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

AB - Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

UR - https://www.scopus.com/pages/publications/0032979512

U2 - 10.1128/aac.43.3.589

DO - 10.1128/aac.43.3.589

M3 - Article

C2 - 10049271

AN - SCOPUS:0032979512

SN - 0066-4804

VL - 43

SP - 589

EP - 591

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 3

ER -

Treatment of murine fusariosis with SCH 56592

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this